A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors (SUMMIT-1)
A Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients With Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Sujatha Venugopal Prasad, M. Sc.
- Phone Number: +1(408)357- 4546
- Email: sprasad@brightpeaktx.com
Study Contact Backup
- Name: Suba Krishnan, MD
- Email: skrishnan@brightpeaktx.com
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Honor Health Research Institute
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- START MidWest
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack Meridian John Theurer Cancer Center
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Carolina Biooncology Institute
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Medical Center
-
-
Texas
-
San Antonio, Texas, United States, 78229
- South Texas Accelerated Research Therapeutics (START)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged ≥18 years at the time of signing informed consent form
- Measurable disease per RECIST 1.1
- Histologically- or cytologically-diagnosed, locally advanced unresectable or metastatic solid tumor. Progressed or recurred after previously having received approved standard of care agents that are approved and available in their local geography.
- ECOG Performance status of 0 or 1
- Life expectancy of at least 3 months
- Adequate organ and marrow function
- Contraception during study participation, as applicable
Exclusion Criteria:
- Has received systemic small molecule therapy or radiation therapy within 28 days prior to the first dose.
- Treatment with biologic agents including anti-PD-1 or PD-L1 antibodies for less than 6 weeks or 5 half-lives, whichever is shorter, prior to first dose.
- Received any investigational agent less than 28 days or 5 half-lives, whichever is shorter, prior to the first dose.
- Treatment with another IL-18 therapy.
- Received systemic immunosuppressive agents greater than the equivalent of prednisone 10mg daily within 14 days of the study, though inhaled, intranasal, topical or intra-articular corticosteroids are allowed.
- Certain clinically significant intercurrent disease.
- Primary immune deficiency.
- Active untreated brain or spine metastasis or leptomeningeal metastases.
- Known HIV seroposivitiy, although patients treated for HIV with no detectable viral load for at least 1 month while on a stable regimen of agents are permitted.
- Active hepatitis A or acute or chroming hepatitis B or C infection.
- Received a live virus vaccine within 30 days of enrollment or a COVD vaccine within 14 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Phase 1a Dose Escalation
Study drug BPT567 at multiple dose levels to define MTD or MAD
|
Immunocytokine infusion
|
|
Experimental: Phase 1b Dose Expansion
Study drug BPT567 at recommended dose for expansion (RDE) cohorts
|
Immunocytokine infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of dose limiting toxicity (DLT), Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)
Time Frame: Duration of first cycle (28 Days) for each cohort evaluated
|
The MTD will be the highest tested dose of BPT567 at which protocol specified number of patients experience DLT or the MAD, highest administered dose in the absence of DLTs
|
Duration of first cycle (28 Days) for each cohort evaluated
|
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time Frame: Through end of study (up to 2 years)
|
Rate of subjects reporting adverse events or serious adverse events including abnormalities in safety laboratory results
|
Through end of study (up to 2 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic parameter - Maximum Concentration (Cmax)
Time Frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
Maximum concentration of BPT567
|
Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
|
Pharmacokinetic parameter - Time to Maximumn Concentration (Tmax)
Time Frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
Time to maximum concentration of BPT567
|
Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
|
Pharmacokinetic parameter - Terminal Elimination Half-life (T1/2)
Time Frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
Terminal elimination half-life of BPT567
|
Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
|
Pharmacokinetic parameter - Area under the plasma concentration curve up to the last quantifiable time-point ((AUC)0-last))
Time Frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
(AUC)0-last of BPT567
|
Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
|
Pharmacokinetic parameter - Area area under the curve from 0 to infinite time (AUC0-inf)
Time Frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
AUC0-inf of BPT567
|
Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)
|
|
Anti-drug Antibody (ADA) Response to BPT567
Time Frame: Predose and postdose at multiple timepoints up to end of treatment (up to 2 years)
|
Number of Participants With Anti-drug Antibody (ADA) Response to BPT567
|
Predose and postdose at multiple timepoints up to end of treatment (up to 2 years)
|
|
Objective response rate (ORR)
Time Frame: Through study completion up to 2 years
|
Per RECIST V1.1
|
Through study completion up to 2 years
|
|
Duration of response (DoR)
Time Frame: Through study completion up to 2 years
|
Per RECIST V1.1
|
Through study completion up to 2 years
|
|
Disease Control Rate (DCR)
Time Frame: Through study completion up to 2 years
|
Per RECIST V1.1
|
Through study completion up to 2 years
|
|
Progression Free Survival (PFS)
Time Frame: Through study completion up to 2 years
|
Per RECIST V1.1
|
Through study completion up to 2 years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate changes in immune cell composition and tumor genome.
Time Frame: Through study completion up to 2 years
|
Peripheral blood and/or tumour biopsy specimens may be analysed in an exploratory manner to assess changes in immune cell composition through immunophenotyping and cytokine level measurements.
|
Through study completion up to 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BPT567-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.